Sionna Therapeutics (SION) EBITDA (2024 - 2026)

Quarterly results put EBITDA at -$27.4 million for Q1 2026, down 65.59% from a year ago — trailing twelve months through Mar 2026 was -$86.0 million (down 30.2% YoY), and the annual figure for FY2025 was -$75.1 million, down 22.47%.

Sionna Therapeutics has reported EBITDA over the past 3 years, most recently at -$27.4 million for Q1 2026.

  • EBITDA reached -$27.4 million in Q1 2026 per SION's latest filing, down from -$20.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$8.7 million in Q2 2024 and bottomed at -$27.4 million in Q1 2026.
  • Median EBITDA over the past 3 years was -$18.2 million (2025), compared with a mean of -$18.2 million.
  • Peak annual rise in EBITDA hit 18.24% in 2025, while the deepest fall reached 109.03% in 2025.
  • Over 3 years, EBITDA stood at -$16.3 million in 2024, then dropped by 25.02% to -$20.3 million in 2025, then crashed by 34.86% to -$27.4 million in 2026.
  • Business Quant data shows EBITDA for SION at -$27.4 million in Q1 2026, -$20.3 million in Q4 2025, and -$20.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -13.63 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -19.70 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -14.44 Mn
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 1.14 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 661.60 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -3.82 Mn
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 201.19 Mn
10 Sionna Therapeutics 1.87 Bn 1.87 Bn - -27.40 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -27.40 Mn
Dec 31, 2025 -20.32 Mn
Sep 30, 2025 -20.04 Mn
Jun 30, 2025 -18.19 Mn
Mar 31, 2025 -16.55 Mn
Dec 31, 2024 -16.25 Mn
Sep 30, 2024 -24.51 Mn
Jun 30, 2024 -8.70 Mn
Mar 31, 2024 -11.86 Mn